1st European Myeloma Network Meeting Turin, Italy, April 19-21, 2018

摘要

Multiple myeloma (MM) is a plasma cell (PC) malignancy, typically char- acterized by monoclonal protein (M-protein) specific biomarkers that are sig- nificant tools for monitoring and form the basis of response criteria. 1 Nonetheless, recent advances in understanding disease biology, along with the availability of high sensitive techniques and the development of several highly effective novel agents, leading to unprecedented high quality re- sponses, have led to changes in the definition of response, and concepts such as depth of response and minimal residual disease (MRD) have been intro- duced. 2 . Extensive data indicate a clear association between the depth of re- sponse and long term outcomes; thus MRD information can potentially be a biomarker of treatment effectiveness.